key: cord-0812178-5rdx7gqr
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: COVID-19 Vaccination and Subclinical Axillary Lymphadenopathy on Mammogram: correspondence
date: 2021-12-27
journal: Acad Radiol
DOI: 10.1016/j.acra.2021.12.024
sha: 0046857aee215e41432d438ff47dba84e2451ef0
doc_id: 812178
cord_uid: 5rdx7gqr

nan

Journal Pre-proof This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Dear Editor, we read with interest the paper "COVID-19 Vaccine-Associated Subclinical Axillary Lymphadenopathy on Screening Mammogram" by Raj et al. [1] where the authors concluded that women who have received either mRNA COVID-19 vaccines may benefit from scheduling their screening mammogram at least 8 weeks after the vaccination. We concur that lymphadenopathy after COVID-19 vaccination might cause a problem in interpreting the mammogram and that having the mammogram before vaccination is useful.

However, during the present pandemic, mass vaccination is needed, and it is often difficult to schedule a timely appointment for a mammogram. In cases in which it is not possible to have a prevaccination mammogram, a mammogram after vaccination is useful. Waiting for 10 weeks, similar to that recommended for nuclear imaging studies [2] , might be appropriate. If the case is urgent, aiming at diagnostic not screening, the mammogram should be done without delay.

COVID-19 Vaccine-Associated Subclinical Axillary Lymphadenopathy on Screening Mammogram

The incidence and duration of COVID-19 vaccine-related reactive lymphadenopathy on (18)F-FD Conflicts of interest